Unknown

Dataset Information

Disclosing Pleiotropic Effects During Genetic Risk Assessment for Alzheimer Disease: A Randomized Trial.


ABSTRACT:

Background

Increasing use of genetic testing raises questions about disclosing secondary findings, including pleiotropic information.

Objective

To determine the safety and behavioral effect of disclosing modest associations between apolipoprotein E (APOE) genotype and coronary artery disease (CAD) risk during APOE-based genetic risk assessments for Alzheimer disease (AD).

Design

Randomized, multicenter equivalence clinical trial. (ClinicalTrials.gov: NCT00462917).

Setting

4 teaching hospitals.

Participants

257 asymptomatic adults were enrolled, 69% of whom had 1 AD-affected first-degree relative.

Intervention

Disclosure of genetic risk information about AD and CAD (AD+CAD) or AD only (AD-only).

Measurements

Primary outcomes were Beck Anxiet

SUBMITTER: Christensen KD 

PROVIDER: S-EPMC4979546 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature